Physician profile
Julie Morris
NPI 1902255573
$3,772.82
in general payments reported to CMS, 2019-2025
23 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $349 · 2022: $303 · 2023: $744 · 2024: $842 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.45 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $412.44 | 2021-2025 | Entyvio, Vpriv, Gattex |
| Janssen Biotech, INC. | $368.30 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $359.50 | 2023-2025 | Xifaxan |
| Pfizer INC. | $289.68 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $261.31 | 2021-2022 | |
| Gilead Sciences, INC. | $214.59 | 2021-2023 | |
| Ardelyx, INC. | $159.54 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $154.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $126.86 | 2024 | |
| Redhill Biopharma INC. | $113.17 | 2021 | |
| Intercept Pharmaceuticals, INC. | $93.55 | 2022-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $83.37 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $79.04 | 2024-2025 | Zenpep, Vowst |
| Amgen INC. | $75.13 | 2021-2023 | Amjevita, Avsola |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $72.91 | 2024-2025 | Omvoh |
| Tersera Therapeutics LLC | $38.09 | 2025 | Quzyttir |
| Phathom Pharmaceuticals, INC. | $33.73 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $29.50 | 2025 | Bylvay |
| Genzyme Corporation | $26.48 | 2025 | |
| Glaxosmithkline, LLC. | $18.89 | 2021 | |
| Digestive Care, INC. | $18.89 | 2025 | Pertzye |
| Celgene Corporation | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.